1Q21 Investor Update
ACCELERATING COMMERCIALIZATION OF
NEW, DISRUPTIVE HEMP/CANNABIS PLANTS
Strategic partnerships enable 22nd Century to capitalize on core strength in plant science
and deliver valuable, commercial-scale plant lines, and IP in two years.
Plant Profile/
Roadmap
anna
Metrix
CannaMetrix's high-throughput
proprietary, human cell-based
cannabinoid assay technology
serves as a roadmap for
developing new hemp/cannabis
plant lines with tailor-made
cannabinoid & terpenoid profiles.
Plant
Biotechnology
KeyGene
Established proprietary
bioinformatics platform and
cutting-edge molecular breeding
platform in partnership with
KeyGene; capabilities include
genetic engineering and plant line
development.
Plant Breeding
& Trials
Currently in advance
discussions with various
partners that will provide 22nd
Century with plant breeding
and trial capability.
Plant
Cultivation
A
NEEDLE ROCK
FARMS
Colorado farm operations
provide 22nd Century with
operational assets
including plant cultivation
capabilities.
Ingredient
Extraction
& Purification
Life
EA
Sciences
22ND CENTURY HAS SECURED FOUR OF THE FIVE KEY PARTNERSHIPS NEEDED TO MAXIMIZE AND SUPPORT
EACH COMPONENT IN UPSTREAM SEGMENT OF THE CANNABINOID VALUE CHAIN.
22nd Century Group, Inc.
Panacea provides 22nd
Century with extraction and
purification services utilizing
proprietary plant lines in
development.
12View entire presentation